Skip to main content
DWTX
NASDAQ Life Sciences

FDA Greenlights Dogwood's SP16 for Chemotherapy Pain, NCI to Fund Phase 1b Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.7
Mkt Cap
$59.789M
52W Low
$1.77
52W High
$9.5
52W Position info
4.0% below low
Off High info
82% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DWTX is trading near its 52-week low of $1.77 (4.0% below the low).

Summary

Dogwood Therapeutics announced FDA acceptance of its Investigational New Drug (IND) application for SP16, a drug candidate targeting chemotherapy-induced pain and neuropathy. This critical regulatory milestone allows the company to proceed with a Phase 1b clinical trial, with patient enrollment anticipated to begin in mid-2026. This development is particularly significant for Dogwood, a small-cap, development-stage biotech whose auditor recently expressed substantial doubt about its ability to continue as a going concern. The Phase 1b trial for SP16 is fully funded by a $2.5 million grant from the National Cancer Institute to its partner, Serpin Pharma, which materially reduces Dogwood's financial burden and conserves its limited capital. This news provides a much-needed positive catalyst, expanding the company's pipeline and offering a new potential value driver. Investors will now watch for the commencement of patient enrollment and future trial results.

At the time of this announcement, DWTX was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $1.77 to $9.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DWTX - Latest Insights

DWTX
Nov 06, 2026, 9:18 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.16 info
Change: +$0.060 (+5%) info
Market Cap: $45.109M info
DWTX
Nov 05, 2026, 8:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $1.16 info
Change: +$0.060 (+5%) info
Market Cap: $45.109M info
DWTX
Oct 19, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.16 info
Change: -$0.200 (-15%) info
Market Cap: $45.109M info
DWTX
Oct 19, 2026, 8:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $1.16 info
Change: -$0.090 (-7%) info
Market Cap: $45.109M info
DWTX
Sep 14, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $1.16 info
Change: -$0.880 (-43%) info
Market Cap: $45.109M info